Abstract
There is an increasing interest in the induced pluripotent stem cells (iPSCs)-based regenerative medicine for various diseases. We have been developing regenerative medicine of spinal cord injury (SCI) by the transplantation of neural stem/progenitor cells (NS/PCs)-transplantation for many years. In a series of our previous efforts, we have addressed the issues of safety and tumorigenesis using iPSCs-derived NS/PCs (iPSCs-NS/PCs). The first-in-human clinical study of iPSC-based cell therapy for subacute SCI was approved by the government on February 18, 2019 as class I regenerative medicine protocol, which will be provided for under Japan's Act on the Safety of Regenerative Medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings for Annual Meeting of The Japanese Pharmacological Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
